# Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606

> **NCT04041648** · PHASE1 · COMPLETED · sponsor: **Pharmosa Biopharm Inc.** · enrollment: 52 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** L606 (Liposomal Treprostinil) Inhalation Solution 51ug
- **DEVICE:** L606 Inhalation System
- **OTHER:** Placebo Solution

## Key facts

- **NCT ID:** NCT04041648
- **Lead sponsor:** Pharmosa Biopharm Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-09
- **Primary completion:** 2019-09-20
- **Final completion:** 2020-05-12
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04041648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04041648, "Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04041648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*